Cognito Therapeutics
- Industry
- Biotechnology
- Founded Year
- 2016
- Headquarters
- 1218 Massachusetts Ave Ste 200, Cambridge, Massachusetts, 02138, United States
- Employee Count
- 70
Key People
- Christian Howell - CEO
- Pritesh Shah - Chief Strategy Officer
- Kimberly Ha - PR & Investor Relations
- Zach Malchano - President
- Martin Williams - VP, BD and Strategic Partnerships
- Mihaly Hajos - CSO
- Divya Dhar - VP of Products
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with significant backgrounds in medical devices and healthcare.
The leadership includes individuals like Pritesh Shah, who has over 20 years in healthcare and medical devices, and Christian Howell, the CEO, indicating a strong foundation in the industry.
- Clinical Need
-
Aspect: Very Strong
Summary: Alzheimer's disease represents a significant unmet medical need with a growing patient population.
With an aging global population, the prevalence of Alzheimer's is increasing, creating a pressing need for effective treatments.
- Competition
-
Aspect: Somewhat crowded
Summary: The Alzheimer's treatment market has multiple players, but Cognito's approach is unique.
Many companies are developing treatments for Alzheimer's, but Cognito's focus on non-invasive neuromodulation sets it apart.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing non-invasive neuromodulation therapies presents moderate technical challenges.
While the concept is innovative, ensuring efficacy and safety through clinical trials is essential.
- Patent
-
Aspect: Strong
Summary: Cognito holds multiple patents related to neural stimulation methods.
Patents such as 'Methods and systems for neural stimulation via visual stimulation' and 'Methods and systems for neural stimulation via auditory stimulation' protect the company's innovations.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding across multiple rounds.
With total funding of $159M, including a $73M Series B round in March 2023, Cognito is well-positioned financially.
- Regulatory
-
Aspect: Pivotal Trial
Summary: Cognito's lead therapy is in a pivotal study and has FDA Breakthrough Device Designation.
The ongoing HOPE pivotal trial and FDA designation indicate significant regulatory progress.
Opportunity Rollup
- Odds of Success
- 3.75
- Peak Market Share
- 4.7
- Segment CAGR
- 4.9%
- Market Segment
- Neurology Devices
- Market Sub Segment
- Alzheimer's Disease Treatment
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.70 |
| 3 | 1.64 |
| 4 | 3.29 |
| 5 | 4.70 |
Key Takeaway
Cognito Therapeutics is well-positioned in the growing Alzheimer's treatment market, leveraging innovative technology and strong leadership to address a significant clinical need.